国产热热热精品,亚洲视频久久】日韩,三级婷婷在线久久,99人妻精品视频,精品九热人人肉肉在线,AV东京热一区二区,91po在线视频观看,久久激情宗合,青青草黄色手机视频

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Pulnovo Medical leads innovation in cardiopulmonary care with state-of-the-art technologies

chinadaily.com.cn | Updated: 2024-11-10 10:30
Share
Share - WeChat

With a focus on innovation, patient-centered care, and collaboration, Pulnovo Medical, a rising star in the realm of innovative medical technology, is making waves in the healthcare industry with its cutting-edge solutions aimed at revolutionizing patient treatment globally.

This year marks a milestone for Pulnovo Medical as it presents its work with an independent booth at the seventh China International Import Expo.

Known as the world's first national-level import-themed expo, the CIIE provides Pulnovo Medical with a prime platform to showcase its innovative technologies to a global audience. Interactive demonstrations at the booth highlight advancements and clinical outcomes of Pulnovo's cutting-edge medical technologies Pulmonary Artery Denervation (PADN) drawing attention to the company's commitment to transformative healthcare solutions.

"By connecting with potential partners, medical institutions, and industry leaders at this influential event, Pulnovo Medical aims to solidify its position as a pioneer in innovative medical solutions and to drive greater awareness of our mission to improve patient outcomes worldwide," said Cynthia Chen, global president of Pulnovo Medical.

Founded with a vision to redefine patient care, reshape treatment paradigm of pulmonary hypertension patients and address critical gaps in cardiopulmonary treatment, Pulnovo Medical has quickly emerged as a frontrunner in this specialized field.

Despite early challenges, such as building a skilled workforce and navigating the complexities of developing advanced medical technologies, the company has achieved notable milestones that underscore its dedication to high-impact innovation.

Among Pulnovo's recent achievements is the successful enrollment of patients in clinical trials across multiple countries, including Portugal, Singapore, and Malaysia, demonstrating its commitment to expanding its reach and gathering crucial data to support further market penetration. This milestone reflects Pulnovo Medical's dedication to delivering advanced solutions to patients worldwide, particularly those dealing with diseases where traditional therapies offer limited relief.

Pulnovo's efforts in clinical research, especially with its innovative PADN technology, have set it apart as a leader in addressing complex cardiopulmonary conditions. PADN technology has shown promise in managing pulmonary hypertension, a challenging condition that affects millions globally. This groundbreaking technology was granted as FDA Breakthrough Designation Device, as well as receiving a both FDA Humanitarian Use Device (HUD) certification and CMS coding approval, facilitating patient access and solidifying Pulnovo's reputation in the global medical field.

"Recognizing the limitations of current therapies, we are driven by the desire to provide innovative treatment solutions to a broader patient population," Chen said.

Pulnovo Medical's expansion efforts reflect a commitment to making its technologies widely available, especially in key markets across Europe, North America, and Asia. The company has also actively pursued partnerships with healthcare providers to foster education and awareness around pulmonary hypertension and heart failure, increasing understanding of these serious conditions and the potential impact of PADN technology.

Looking ahead, Pulnovo Medical is setting ambitious goals. "In the next three to five years, Pulnovo Medical aims to further expand its global presence and advance PADN technology through ongoing clinical research to support more pulmonary hypertension patients," Chen said.

As part of its global expansion strategy, Pulnovo is keen to foster collaborations with international healthcare institutions and participate in major industry events, such as the CIIE, to build a network that supports its mission.

Through its advancements in technology, strategic global partnerships, and commitment to improving patient outcomes, Pulnovo Medical is emerging as a leader that could reshape the future of healthcare in cardiopulmonary care.

"We plan to strengthen our partnerships with healthcare providers and institutions globally to promote education and awareness of pulmonary hypertension and heart failure, along with the benefits of our solutions," added Chen.

Top
BACK TO THE TOP
English
Copyright 1994 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
建湖县| 呼和浩特市| 东方市| 会泽县| 卢氏县| 永济市| 福贡县| 通河县| 德江县| 桦南县| 米林县| 珲春市| 青河县| 慈溪市| 大埔县| 碌曲县| 武义县| 九寨沟县| 克什克腾旗| 塔城市| 金华市| 会理县| 平乡县| 五河县| 仙桃市| 山丹县| 黑龙江省| 竹山县| 榆中县| 栾城县| 缙云县| 鄱阳县| 紫金县| 余庆县| 织金县| 八宿县| 大荔县| 岐山县| 白朗县| 昌宁县| 昆明市|